Literature DB >> 34971417

Left ventricular structure and function in patients with chronic kidney disease assessed by 3D echocardiography: the CPH-CKD ECHO study.

Jacob Christensen1,2, Nino Emanuel Landler3,4, Flemming Javier Olsen3, Bo Feldt-Rasmussen5,6, Ditte Hansen5,7, Anne-Lise Kamper6, Christina Christoffersen8, Ellen Linnea Freese Ballegaard5,6, Ida Maria Hjelm Sørensen5,6, Sasha Saurbrey Bjergfelt5,6, Eline Seidelin7, Susanne Bro6, Tor Biering-Sørensen3,8.   

Abstract

Cardiovascular disease is the leading cause of mortality amongst patients with chronic kidney disease (CKD). This is the first study using 3-dimensional echocardiography (3DE) to investigate associations between adverse changes of the left ventricle, and different stages of CKD. Participants were recruited from the Copenhagen CKD cohort study and the Herlev-Gentofte CKD cohort study. Patients were stratified according to GFR category (G1 + 2: eGFR ≥ 60 mL/min/1.73 m2, G3: eGFR = 30-59 mL/min/1.73 m2, and G4 + 5: eGFR ≤ 29 mL/min/1.73 m2), and according to albuminuria (A1: UACR < 30 mg/g, A2: 30-300 mg/g, A3: > 300 mg/g). Echocardiograms were analysed for left ventricular (LV) mass index (LVMi), LV ejection fraction (LVEF), and global strain measures. In adjusted analysis, eGFR groups were adjusted for confounders and albuminuria category, while albuminuria groups were adjusted for confounders and GFR category. The study population consisted of 662 outpatients with CKD and 169 controls. Mean age was 57 ± 13 years, and 61% were males. Mean LVEF and global longitudinal strain (GLS) were increasingly impaired across eGFR groups: LVEF = 60.1%, 58.4%, and 57.8% (p = 0.013), GLS =  - 16.1%, - 14.8%, and - 14.6% (p < 0.0001) for G1 + 2, G3, and G4 + 5. LVMi and prevalence of LV hypertrophy increased with albuminuria severity: mean LVMi = 87.9 g/m2, 88.1 g/m2, and 92.1 g/m2 (p = 0.007) from A1-3. Adjusted analysis confirmed reduced LVEF in G3 compared with G1 + 2, and increased LVMi in A3 compared with A1. Increasingly impaired eGFR was associated with adverse changes in LV systolic function, while albuminuria was associated with adverse changes in LV mass assessed by 3DE. Their associations were independent of each other.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  3D echocardiography; 3D speckle tracking echocardiography; Chronic kidney disease; Left ventricular hypertrophy

Year:  2021        PMID: 34971417     DOI: 10.1007/s10554-021-02507-6

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  24 in total

1.  Cause-Specific Deaths in Non-Dialysis-Dependent CKD.

Authors:  Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Joseph V Nally
Journal:  J Am Soc Nephrol       Date:  2015-06-04       Impact factor: 10.121

2.  Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study.

Authors:  Mahboob Rahman; Dawei Xie; Harold I Feldman; Alan S Go; Jiang He; John W Kusek; James Lash; Edgar R Miller; Akinlolu Ojo; Qiang Pan; Stephen L Seliger; Susan Steigerwalt; Ray R Townsend
Journal:  Am J Nephrol       Date:  2014-11-11       Impact factor: 3.754

3.  Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.

Authors:  Janani Rangaswami; Vivek Bhalla; John E A Blair; Tara I Chang; Salvatore Costa; Krista L Lentine; Edgar V Lerma; Kenechukwu Mezue; Mark Molitch; Wilfried Mullens; Claudio Ronco; W H Wilson Tang; Peter A McCullough
Journal:  Circulation       Date:  2019-04-16       Impact factor: 29.690

4.  Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy.

Authors:  Wolfgang Lieb; Bjoern Mayer; Jan Stritzke; Angela Doering; Hans-Werner Hense; Hannelore Loewel; Jeanette Erdmann; Heribert Schunkert
Journal:  Nephrol Dial Transplant       Date:  2006-07-31       Impact factor: 5.992

5.  Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Andrew A House; Christoph Wanner; Mark J Sarnak; Ileana L Piña; Christopher W McIntyre; Paul Komenda; Bertram L Kasiske; Anita Deswal; Christopher R deFilippi; John G F Cleland; Stefan D Anker; Charles A Herzog; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Peter A McCullough
Journal:  Kidney Int       Date:  2019-04-30       Impact factor: 10.612

6.  Impaired Left Ventricular Global Longitudinal Strain among Patients with Chronic Kidney Disease and End-Stage Renal Disease and Renal Transplant Recipients.

Authors:  Maura Ravera; Gian Marco Rosa; Paolo Fontanive; Elisabetta Bussalino; Ulrico Dorighi; Daniela Picciotto; Luca Di Lullo; Frank Lloyd Dini; Ernesto Paoletti
Journal:  Cardiorenal Med       Date:  2018-11-28       Impact factor: 2.041

7.  Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study.

Authors:  Alberto Martínez-Castelao; José L Górriz; José M Portolés; Fernando De Alvaro; Aleix Cases; José Luño; Juan F Navarro-González; Rafael Montes; Juan J De la Cruz-Troca; Aparna Natarajan; Daniel Batlle
Journal:  BMC Nephrol       Date:  2011-10-05       Impact factor: 2.388

Review 8.  The link between chronic kidney disease and cardiovascular disease.

Authors:  Sarmad Said; German T Hernandez
Journal:  J Nephropathol       Date:  2014-07-01

9.  Counterclockwise and Clockwise Rotation of QRS Transitional Zone: Prospective Correlates of Change and Time-Varying Associations With Cardiovascular Outcomes.

Authors:  Siddharth Patel; Lucia Kwak; Sunil K Agarwal; Larisa G Tereshchenko; Josef Coresh; Elsayed Z Soliman; Kunihiro Matsushita
Journal:  J Am Heart Assoc       Date:  2017-11-03       Impact factor: 5.501

10.  Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD.

Authors:  Thomas A Mavrakanas; Aisha Khattak; Karandeep Singh; David M Charytan
Journal:  BMC Nephrol       Date:  2018-07-11       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.